We are live on
!
Find out more
Kiniksa Pharmaceuticals
KNSA
KNSA
61 hedge funds and large institutions have $224M invested in Kiniksa Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
9% more funds holding
Funds holding: 56 → 61 (+5)
0.67% less ownership
Funds ownership: 87.56% → 86.89% (-0.67%)
24% less capital invested
Capital invested by funds: $295M → $224M (-$71.1M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
61
Holders Change
+5
Holders Change %
+8.93%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
26
Reduced
14
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.82M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.28M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.7M |
| 4 |
BlackRock
New York
|
+$2.16M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.46M |
Top Sellers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.88M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.36M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$3.11M |
| 4 |
NC
Nexthera Capital
New York
|
-$1.22M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.07M |
